Pulmonary hypertension associated with antisynthetase syndrome: insights from the ASPIRE registry
Rheumatology Advances in Practice · 13.11.2026
DOI: 10.1093/rap/rkag147 ↗Kurz gefasst
Fachartikel in der Zeitschrift Rheumatology Advances in Practice, online erschienen am 13.11.2026. Verfasst von Miriam F Cox und 16 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objectives
To assess the characteristics and outcomes in patients with Pulmonary Hypertension (PH) associated with Antisynthetase syndrome (ASyS).
Methods
Data for 88 ASyS patients assessed between 2000 and 2022 were obtained from the ASPIRE (Assessing the Spectrum of PH identified at a Referral centre) registry. Patients with pre-capillary PH were matched for age, sex and severity of PH with systemic sclerosis controls on a 1:1 basis.
Results
64 patients had pre-capillary PH, 9 PH associated with left heart disease and 15 had no/unclassified-PH. Jo-1 was the most common antibody and was present more frequently in pre-capillary PH. Most patients had interstitial lung disease; nonspecific interstitial pneumonia was most common. Jo-1 antibodies were associated with an increased risk of PH and of more severe lung disease. Patients with pre-capillary PH had significantly worse spirometry, diffusing capacity of the lungs for carbon monoxide (DLco) and a trend towards more extensive interstitial lung disease than patients with no/unclassified-PH. In patients with ASyS-PH, higher age and increased pulmonary vascular resistance were independent predictors of mortality. 10-year survival was significantly worse in patients with pre-capillary PH than no/unclassified-PH. Despite less favourable spirometry, 10-year survival was significantly better in ASyS-PH than in systemic sclerosis-associated PH.
Conclusion
Most patients with ASyS-PH have parenchymal lung disease. Age and pulmonary vascular resistance are important prognostic predictors. Survival in ASyS-PH is superior to that of systemic sclerosis-associated pre-capillary PH.
Zitieren
APA
Cox, M. F., Alabed, S., Akil, M., Charalampopoulos, A., Elliot, C. A., Hameed, A., Hamilton, N., Hurdman, J., Jade, J., Kiely, D. G., Kilding, R., Kuet, K., Rothman, A. M. K., Smith, H., Swift, A. J., Thompson, A. A. R., & Condliffe, R. (2026). Pulmonary hypertension associated with antisynthetase syndrome: insights from the ASPIRE registry. Rheumatology Advances in Practice. https://doi.org/10.1093/rap/rkag147
Vancouver
Cox MF, Alabed S, Akil M, Charalampopoulos A, Elliot CA, Hameed A, et al. Pulmonary hypertension associated with antisynthetase syndrome: insights from the ASPIRE registry. Rheumatology Advances in Practice. 2026. doi:10.1093/rap/rkag147
BibTeX
@article{Cox2026,
author = {Cox, Miriam F and Alabed, Samer and Akil, Mohammed and Charalampopoulos, Athanasios and Elliot, Charlie A and Hameed, Abdul and Hamilton, Neil and Hurdman, Judith and Jade, Judith and Kiely, David G and Kilding, Rachael and Kuet, Kar-Ping and Rothman, Alexander M K and Smith, Howard and Swift, Andrew J and Thompson, A A Roger and Condliffe, Robin},
title = {Pulmonary hypertension associated with antisynthetase syndrome: insights from the ASPIRE registry},
journal = {Rheumatology Advances in Practice},
year = {2026},
doi = {10.1093/rap/rkag147}
}
EUVIMED